• Scienture announces new US patent covering Rezenopy naloxone nasal spray

  Scienture Holdings, which acquired US rights to Summit Biosciences’s Rezenopy naloxone nasal spray in March 2025, announced that the United States Patent and Trademark Office has granted Summit US Patent No. 12,622,903 B2 covering Rezenopy… [Read more . . .]

• Nebu-Flow gets £2 million Scottish Enterprise grant for continued development of its nebulizer technology

  University of Glasgow spin-out Nebu~Flow has received a Scottish Enterprise grant worth £2 million “to accelerate development and patient access to its patented nebulizer technology in the UK and globally,” the company said. The company… [Read more . . .]

• FDA approves MannKind’s sBLA for pediatric use of Afrezza insulin DPI

  MannKind Corporation announced that the FDA has approved the company’s sBLA for use of Afrezza inhaled dry powder insulin for the treatment of Type 1 and Type 2 diabetes in children aged 6 and older. Afrezza was… [Read more . . .]

• Kvvit acquires rights to Merz’s Inbrija levodopa DPI in mainland China, Hong Kong, and Macao

  Jiangxi Kvvit Pharmaceutical is paying an undisclosed amount up front, plus potential milestones and royalties, to Merz Therapeutics to acquire the rights to develop and commercialize Merz’s Inbrija levodopa dry powder inhaler in mainland China,… [Read more . . .]

• Inhaled SSO developer Rage Bio rebrands as Atisama Therapeutics

  Australian biotech Rage Bio, which has been developing an inhaled splice-switching oligonucleotide (SSO) for the treatment of COPD, has announced that it has changed its name to Atisama Therapeutics. According to the announcement, the name… [Read more . . .]

• FDA tentatively approves Lupin’s ANDA for generic of Yupelri revefenacin inhalation solution

• Quince Therapeutics to acquire Orphai Therapeutics and its LAM-001 rapamycin DPI

• SNBL announces new effort to get Satsuma’s Atzumi DHE nasal powder for migraine into the US market

• Vertex ceases development of VX-522 inhaled RNA therapy for CF after stopping Phase 1/2 trial due to tolerability issues

• Enterprise Therapeutics says Phase 2 trial of ETD001 inhaled ENaC blocker for CF met its primary endpoint

More news . . .